Correction to: A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
More News: Antiphospholipid Syndrome | Drugs & Pharmacology | Hughes Syndrome | Investigational New Drugs | Study | Thrombosis